Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer — AMEERA-3

Breast Cancer Metastatic Clinical Trial

Official title:
An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies

Status Active, not recruiting

Clinical Trial Summary

Primary Objective: To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer Secondary Objectives: - To compare the overall survival in the 2 treatment arms - To assess the objective response rate in the 2 treatment arms - To evaluate the disease control rate in the 2 treatment arms - To evaluate the clinical benefit rate in the 2 treatment arms - To evaluate the duration of response in the 2 treatment arms - To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms - To evaluate the pharmacokinetics of amcenestrant as single agent - To evaluate health-related quality of life in the 2 treatment arms - To compare the overall safety profile in the 2 treatment arms

Clinical Trial Description

The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or until the participant receive another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, death or upon participant's request to stop treatment, or Investigator decision, whichever occurs first. An extension of recruitment for Chinese participants is planned in this study: After completion of randomization in the global part of the study, randomization will continue in China until approximately 90 Chinese participants are randomized. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04059484
Study type	Interventional
Source	Sanofi
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 22, 2019
Completion date	September 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Active, not recruiting	`NCT04509596` - DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer	Phase 1
Recruiting	`NCT04122469` - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease	N/A
Completed	`NCT03045653` - Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer	Phase 2
Terminated	`NCT03322215` - HR+/HER2- Advanced Breast Cancer and Endocrine Resistance	Phase 2
Recruiting	`NCT04368442` - Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
Terminated	`NCT03709082` - Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer	Phase 1/Phase 2
Terminated	`NCT03642990` - NR in Chemo-induced Peripheral Neuropathy	Phase 2
Terminated	`NCT01876251` - A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer	Phase 1
Completed	`NCT04483505` - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.	Phase 1
Recruiting	`NCT03086785` - Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer	Phase 2
Terminated	`NCT04197999` - A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer	Phase 1
Not yet recruiting	`NCT06439693` - The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer	Phase 2
Not yet recruiting	`NCT03638765` - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer	Phase 1
Recruiting	`NCT06100874` - A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)	Phase 2
Completed	`NCT05609903` - Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
Active, not recruiting	`NCT04597580` - Personalised Disease Monitoring in Metastatic Breast Cancer
Completed	`NCT05301530` - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.	Phase 1
Active, not recruiting	`NCT03328884` - Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients	Phase 2
Recruiting	`NCT05837533` - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients	N/A